These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

61 related articles for article (PubMed ID: 16253502)

  • 21. Efficacy and safety of the combination of rituximab, fludarabine, and mitoxantrone for rituximab-naive, recurrent/refractory follicular non-Hodgkin lymphoma with high tumor burden: a multicenter phase 2 trial by the Groupe d'Etude des Lymphomes de l'Adulte (GELA) and Groupe Ouest Est des Leucémies et Autres Maladies du Sang (GOELAMS).
    Morschhauser F; Mounier N; Sebban C; Brice P; Solal-Celigny P; Tilly H; Feugier P; Fermé C; Copin MC; Lamy T
    Cancer; 2010 Sep; 116(18):4299-308. PubMed ID: 20549824
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma.
    Fisher RI; Gaynor ER; Dahlberg S; Oken MM; Grogan TM; Mize EM; Glick JH; Coltman CA; Miller TP
    N Engl J Med; 1993 Apr; 328(14):1002-6. PubMed ID: 7680764
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group.
    Unterhalt M; Herrmann R; Tiemann M; Parwaresch R; Stein H; Trümper L; Nahler M; Reuss-Borst M; Tirier C; Neubauer A; Freund M; Kreuser ED; Dietzfelbinger H; Bodenstein H; Engert A; Stauder R; Eimermacher H; Landys K; Hiddemann W
    Leukemia; 1996 May; 10(5):836-43. PubMed ID: 8656680
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I/II trial of nonpegylated liposomal doxorubicin, cyclophosphamide, vincristine, and prednisone in the treatment of newly diagnosed aggressive non-Hodgkin's lymphoma.
    Tulpule A; Espina BM; Berman N; Buchanan LH; Smith DL; Sherrod A; Dharmapala D; Gee C; Boswell WD; Nathwani BN; Welles L; Levine AM
    Clin Lymphoma Myeloma; 2006 Jul; 7(1):59-64. PubMed ID: 16879771
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A randomized trial of high dose cyclophosphamide, vincristine, and prednisone plus or minus doxorubicin (CVP versus CAVP) with long-term follow-up in advanced non-Hodgkin's lymphoma.
    Bishop JF; Wiernik PH; Wesley MN; Kaplan RS; Diggs CH; Barcos MP; Sutherland JC
    Leukemia; 1987 Jun; 1(6):508-13. PubMed ID: 3669768
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Community-based trial of R-CHOP and maintenance rituximab for intermediate- or high-grade non-Hodgkin lymphoma with first-cycle filgrastim for older patients.
    Case DC; Desch CE; Kalman LA; Vongkovit P; Mena RR; Fridman M; Allen B
    Clin Lymphoma Myeloma; 2007 Mar; 7(5):354-60. PubMed ID: 17562245
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A clinical observation of fludarabine-containing regimens in the treatment of low grade non-Hodgkin's lymphoma].
    Lü SQ; Yang JM; Song XM; Chen L; Zhang WP; Ni X; Xu XQ; Wang JM
    Zhonghua Zhong Liu Za Zhi; 2007 Sep; 29(9):710-2. PubMed ID: 18246806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Fludarabine, cyclophosphamide, and rituximab for the treatment of patients with chronic lymphocytic leukemia or indolent non-Hodgkin lymphoma.
    Tam CS; Wolf M; Prince HM; Januszewicz EH; Westerman D; Lin KI; Carney D; Seymour JF
    Cancer; 2006 Jun; 106(11):2412-20. PubMed ID: 16649223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Addition of rituximab to reduced-dose CHOP chemotherapy is feasible for elderly patients with diffuse large B-cell lymphoma.
    Shin HJ; Chung JS; Song MK; Kim SK; Choe S; Cho GJ
    Cancer Chemother Pharmacol; 2012 May; 69(5):1165-72. PubMed ID: 22215473
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The addition of interferon or high dose cyclophosphamide to standard chemotherapy in the treatment of patients with multiple myeloma: phase III Eastern Cooperative Oncology Group Clinical Trial EST 9486.
    Oken MM; Leong T; Lenhard RE; Greipp PR; Kay NE; Van Ness B; Keimowitz RM; Kyle RA
    Cancer; 1999 Sep; 86(6):957-68. PubMed ID: 10491521
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Low-grade non-Hodgkin's lymphomas. Study of 73 cases].
    Coma A; Jonte F; Zanabili Y; Soto I; Fanjul F; Carrera D; Rayón C; Luño E; Jalón S; Pinto V
    Sangre (Barc); 1992 Aug; 37(4):249-54. PubMed ID: 1514137
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pilot study of modified version of CHOP plus radiotherapy for early-stage aggressive non-Hodgkin's lymphoma of the head and neck.
    Nishioka T; Tsuchiya K; Nishioka S; Kitahara T; Ohmori K; Homma A; Aoyma H; Shindoh M; Shirato H
    Int J Radiat Oncol Biol Phys; 2004 Nov; 60(3):847-52. PubMed ID: 15465202
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A phase I trial to assess the value of recombinant human granulocyte colony stimulating factor (R-MeTHuG-CSF, filgrastim) in accelerating the dose rate of chemotherapy for intermediate and high-grade non-Hodgkin's lymphoma (NHL). The Central Lymphoma Group.
    Smith GM; Child JA; Cullen MH; Bailey NP; Woodruffe CM; Fletcher J; Earl H; Barnard D
    Hematol Oncol; 1996 Dec; 14(4):193-201. PubMed ID: 9267465
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma.
    Akpek G; Koh HK; Bogen S; O'Hara C; Foss FM
    Cancer; 1999 Oct; 86(7):1368-76. PubMed ID: 10506727
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group.
    Nickenig C; Dreyling M; Hoster E; Pfreundschuh M; Trumper L; Reiser M; Wandt H; Lengfelder E; Unterhalt M; Hiddemann W;
    Cancer; 2006 Sep; 107(5):1014-22. PubMed ID: 16878325
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phase II trial of fludarabine monophosphate as first-line treatment in patients with advanced follicular lymphoma: a multicenter study by the Groupe d'Etude des Lymphomes de l'Adulte.
    Solal-Céligny P; Brice P; Brousse N; Caspard H; Bastion Y; Haïoun C; Bosly A; Tilly H; Bordessoule D; Sebban C; Harousseau JL; Morel P; Dupas B; Plassart F; Vasile N; Fort N; Leporrier M
    J Clin Oncol; 1996 Feb; 14(2):514-9. PubMed ID: 8636765
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Issues for the future development of fludarabine phosphate.
    Cheson BD
    Semin Oncol; 1990 Oct; 17(5 Suppl 8):71-8. PubMed ID: 1699286
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacokinetic study of single doses of oral fludarabine phosphate in patients with "low-grade" non-Hodgkin's lymphoma and B-cell chronic lymphocytic leukemia.
    Foran JM; Oscier D; Orchard J; Johnson SA; Tighe M; Cullen MH; de Takats PG; Kraus C; Klein M; Lister TA
    J Clin Oncol; 1999 May; 17(5):1574-9. PubMed ID: 10334546
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fludarabine, adriamycin and dexamethasone (FAD) in newly diagnosed advanced follicular lymphoma: a phase II study by the British National Lymphoma Investigation (BNLI).
    Yung L; Cunningham D; Hancock B; Smith P; Maclennan K; Linch D; McMillan A
    Br J Cancer; 2004 Aug; 91(4):695-8. PubMed ID: 15280929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.